USE OF PROTEINS AS ANTI-RETROVIRAL AGENTS

Abstract: The present invention relates to the use of a protein, extracted with perchloric acid from animal organs, for the preparation of medicaments with anti-retroviral activity, and, in particular, against HIV, the Human Immunodeficiency Virus.

Description: USE OF PROTEINS AS ANTT-RETROVTRA AGENTS The present invention relates to the use of a protein of a molecular weight of about 14 Kda, extracted from animal organs, for the preparation of medicaments with anti-retroviral activity, in particular against HIV, the Human Immunodeficiency Virus. The therapeutical problems related with infection of the HIV retrovirus are well known. In particular, the increasing diffusion of the infection and the severity of the disease caused by the virus, known as Acquired Immunodeficiency Syndrome or AIDS, induced great research efforts which are producing promising results in terms of possibility of control and therapy of the infection. For example, the protease inhibitors have recently joined the reverse transcriptase inhibitors, such as azidothymidine. Moreover, the researches for the development of prophylactic or therapeutical vaccines continue, although they have, up to now, been hampered by the remarkable capability of HIV to escape the immune system thanks to continuous mutations. On the other hand, the main problem with pharmacological therapy lies in the onset of resistance to the medicaments used. Recently it has been found that proteins extractable with perchloric acid from mammalian organs, described in WO 92/10197, are capable of inhibiting the ill vitro viral replication, inducing an immune and cytotoxic response to lymphocytes infected by the virus in patients affected by AIDS. The protein having the following sequence showed to be particularly active: Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala 1 5 10 Pro Ala Ala lie Gly Pro Tyr Ser Gin Ala Val Leu Val Asp 15 20 25 Arg Thr lie Tyr lie Ser Gly Gin Leu Gly Met Asp Pro Ala 30 35 40 Ser Gly Gin Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys 45 50 55 Gin Ala Leu Thr Asn lie Gly Glu lie Leu Lys Ala Ala Gly 60 65 70 Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala 75 80 Asp lie Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gin 85 90 95 Tyr Phe Gin Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gin Val 100 105 110 Ala Ala Leu Pro Lys Gly Gly Arg Val Glu lie Glu Ala lie 115 120 125 Ala Val Gin Gly Pro Leu Thr Thr Ala Ser Val 130 135 Said protein, in the following referred to as pl4, having molecular weight of about 14 Kd, can be obtained by perchloric extraction of mammals livers and subsequent purification by dialysis, HPLC and hydrophobic exchange chromatography, according to the protocol described in O96/02567. The invention also relates to the use of proteins having at least an 80% (preferably 90%) homology with the sequence reported above. Proteins with sequences very similar to that reported above, isolated from goat liver, have been described by a number of authors (for example: Levy-Favatier et al., in Eur. J. Biochem. 1903, 212(3), 665-73) which desumed the sequence from the cDNA recovered from different animal species, in particular from rat liver. The anti-HIV activity elicited by the pl4 protein has been demonstrated using sera dotained from animals or humans previously immunized with pl4. For this purpose, the protein was administered subcutaneously at doses of 1-2 mg every seven days for 4-6 weeks, until reaching a significant anti-pl4 antibody titre. The resulting sera were incubated on E-line cells (a derivative of human T-lymphocytes cell line HuT78 chronically infected with the HIV-1 SF 2 virus) or normal, non-infected, HuT78 cells. Said cells were mixed in a 1:1000 ratio (1 cell E- line producing virus each 1000 normal cells Hut78) plated on 24-well plates at a concentration of 1x10 s cells/well in 1 ml of RPMI 1640 culture medium containing 5% of foetal bovine serum and antibiotics. Each well was then added with the test serum at a 5% final concentration so as to reach a 10% final total serum concentration. Control samples received the RPMI 1640 culture medium containing 5% of foetal bovine serum and 5% of normal human serum. As a positive control, rabbit anti HIV-1 hyperimmune sera were used, which were able to inhibit the viral infectivity by about 3 log. After 5 days of incubation, the culture media were centrifuged and quantification of the produced virus was done by the HIV-1 p24 core antigen capture assay. The tested sera have shown high inhibition percentage, suggesting a therapeutical activity of pl4 protein, which could be used as immunogenic antigen. Antibodies raised against this protein could be used as well . Such an activity has in fact been confirmed, although up to now in a limited number of cases, also in vivo in HIV-positive and in clinically ill AIDS patients. Six patients were treated subcutaneously for four weeks with 1 mg of pl4 every 7 days. After each injection and before the treatment, the following parameters were measured: T4/T8 ratio; number of rosette receptors; total lymphocytes' number; - T4 increase; B cells' number; granulocytes ' number . At the end of the treatment the serological parameters tended to improve and the hematological pattern showed a normalization. Some years after the treatment, the patients are still alive and their conditions quite satisfactory. The pl4 protein can be administered, according to the invention, in the form of suitable formulations, usually injectable, optionally containing conventional adjuvants such as aluminium hydroxide, polysaccharides, carrier proteins etc.. The procedure of administration (doses, frequency of administration, etc. ) will be determined according to the circumstances, depending on different factors such as conditions of the patient, stage of the disease, hematological and serological parameters. Anti-pl4 antibody titre can be used for monitoring the therapy, together with the common parameters used for the immunological functionality. Generally, a subcutaneous injection of a protein dose ranging from 0.1 to 10 mg, (preferably from 1 to 2 mg), can be administered every week for 3-6 weeks or, anyhow, until an objective therapeutical response is obtained. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: zeteεis s.p.a. (B) STREET: Galleria del Corso 2 (C) CITY: Milano (E) COUNTRY: Italy (F) POSTAL CODE (ZIP): 20122 (ii) TITLE OF INVENTION: use of proteins as anti- retroviral agents (iϋ) NUMBER OF SEQUENCES: 1 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala 1 5 10 Pro Ala Ala He Gly Pro Tyr Ser Gin Ala Val Leu Val Asp 15 20 25 Arg Thr He Tyr He Ser Gly Gin Leu Gly Met Asp Pro Ala 30 35 40 Ser Gly Gin Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys 45 50 55 Gin Ala Leu Thr Asn He Gly Glu He Leu Lys Ala Ala Gly 60 65 70 Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala 75 80 Asp He Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gin 85 90 95 Tyr Phe Gin Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gin Val 100 105 110 Ala Ala Leu Pro Lys Gly Gly Arg Val Glu He Glu Ala He 115 120 125 Ala Val Gin Gl IyX Pro Leu Thr Thr Ala Ser Val 130 135

Claims: CLAIMS 1. The use of proteins extractable from mammalian liver with perchloric acid for the preparation of medicaments to treat infections caused by HIV, the Human Immunodeficiency Virus. 2. The use, according to claim 1, of the above mentioned preparation in which the active protein has the following sequence : Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala 1 5 10 Pro Ala Ala He Gly Pro Tyr Ser Gin Ala Val Leu Val Asp 15 20 25 Arg Thr He Tyr He Ser Gly Gin Leu Gly Met Asp Pro Ala 30 35 40 Ser Gly Gin Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys 45 50 55 Gin Ala Leu Thr Asn He Gly Glu He Leu Lys Ala Ala Gly 60 65 70 Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala 75 80 Asp He Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gin 85 90 95 Tyr Phe Gin Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gin Val 100 105 110 Ala Ala Leu Pro Lys Gly Gly Arg Val Glu He Glu Ala He 115 120 125 Ala Val Gin Gly Pro Leu Thr Thr Ala Ser Val 130 135 3. The use, according to claim 1, of proteins having at least 80% homology with the sequence presented in claim 2. 4. Pharmaceutical compositions containing, as an active ingredient, the proteins of claims 1-3 together with adeguate adjuvants. 5. Compositions, according to claim 4, in which the adjuvants are selected among aluminium hydroxide, polysaccharides or carrier proteins

Inventors: BARTORELLI ALBERTO, DE GIULI MORGHEN CARLO, BARTORELLI, ALBERTO, DE GIULI MORGHEN, CARLO
Applicants: BARTORELLI ALBERTO, GIULI MORGHEN CARLO DE, ZETESIS SPA, BARTORELLI, ALBERTO, DE GIULI MORGHEN, CARLO, ZETESIS S.P.A.
Application year: 1997
Main classification: C07K14
IPC codes: A61K35, A61K38, A61P31, C07K14